Refine by
Patient Registry Articles & Analysis
33 news found
Baliga BIOS-03: Real world clinical outcomes of patients with diffuse midline glioma in a longitudinal outcomes registry Timothy J. Stuhlmiller, Asher Wasserman, Jameson Quinn, Zac Cole, Alaa Awawda, Sabrina Irizarry, Sebastian Williams, Mark Shapiro, Al Musella, Santosh Kesari “I’m proud to present these analyses of real-world data and clinical ...
ByxCures
This is paving the way for improving patient care as ePROMs can be used to monitor patients with reported health conditions coming directly from the patient, so caregivers and clinicians can know about the patient’s health concerns outside the clinical setting. ...
(NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-day outcomes from the fully-enrolled 500-patient CLOUT registry. The company also reported positive results from a ...
Lewis founded the Alberta Prostate Cancer Research Institute (APCaRI), an international collaborative network of prostate cancer scientists, physicians, healthcare employees, and patients. APCaRI’s mission is to accelerate the translation of prostate cancer research from the laboratory to the clinic to improve the lives of men with prostate cancer. Through APCaRI, the Lewis ...
(NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”). ...
First, the in-hospital and 30-day results from the fully enrolled 800-patient US cohort of the FLASH registry will be presented at the TCT conference in Boston on September 18th. ...
Pittsburgh, PA – (May 9, 2022) – Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program for people who are affected by pelvic radiation exposure, including survivors of pelvic cancers, such as prostate, uterine, cervical and colon cancer. ...
“We look forward to sharing updates at the National Kidney Foundation’s Spring Clinical Meetings, including the design of a prospective observational registry of patients treated with LUPKYNIS.” Presentations related to LUPKYNIS at the meetings include: Title: “The Efficacy of Voclosporin in Lupus Nephritis is Independent of Changes in ...
Additional MBCC Poster Presentations Include: Posters will be available online for viewing during the duration of the conference and available in-person during the poster receptions on March 3rd and 4th The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients with DCIS ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle ...
-based prospective, observational registry of adult patients with LN treated with LUPKYNIS. The registry is intended to support the interests of patients, clinicians, regulatory bodies, payers and industry by obtaining longitudinal data on LUPKYNIS. ...
After enrolling two patients in the study, enrollment was suspended in 2020 due to COVID-19 restrictions. Those restrictions have now been lifted and patient recruitment has resumed (Clinical trials registry NCT03027388). Up to 20 patients may be enrolled to obtain 8 evaluable subjects. A two-stage design will be used. ...
“Several studies have shown that even small amounts of visual field loss can lead to limitations in common activities such as driving, reading, and a patient’s ability to exercise or go outside the house. Combining Hydrus with cataract surgery is an opportunity to treat patients early in their disease state. ...
Patient registries play a critical role in the development of treatments for rare diseases – 95% of which are still without an approved therapy today. ...
Food and Drug Administration approved a modification of labeling for the Optimizer Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement. Since patients are no longer required to be in NSR at the time of Optimizer implant, heart rhythm does not impose any restrictions on patients eligible for ...
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. ...
Pittsburgh, PA – (April 30, 2021) – The Bladder Health Foundation announces the rollout of the first on-line patient registry for pelvic radiation cancer survivors. The online registry is located at www.radiationcystitis.com The Bladder Health Foundation, with support from Lipella Pharmaceuticals Inc., is promoting the awareness of ...
Ataxia UK is the leading charity in the United Kingdom for people affected by ataxia - an umbrella term for a group of neurological disorders that target the nervous system and affect balance, coordination and speech. FARA (Friedreich’s Ataxia Research Alliance) is a non-profit organisation in the US, dedicated to supporting research into treatments and cures for Friedreich’s ataxia, ...
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif. ...
It was designed to demonstrate the safety and efficacy of the Hydrus Microstent for lowering intraocular pressure (IOP) in glaucoma patients undergoing planned cataract surgery. Patients were randomized 2:1 to receive cataract surgery plus the Hydrus Microstent or cataract surgery alone, respectively. ...